胫骨重建中如何预测同种异体结构移植物的存活。

IF 1.4 4区 医学 Q4 CELL BIOLOGY
R Evrard, J Manon, P-L Docquier, O Cornu, T Schubert
{"title":"胫骨重建中如何预测同种异体结构移植物的存活。","authors":"R Evrard, J Manon, P-L Docquier, O Cornu, T Schubert","doi":"10.1007/s10561-025-10172-5","DOIUrl":null,"url":null,"abstract":"<p><p>Tibial reconstruction for major bone loss is a challenging surgical situation. For more than 30 years, massive bone allografts entered our therapeutic arsenal as a major tool to reconstruct large bone defect. Despite allograft is valued for its convenience, it is still burdened by a high complication rate. This retrospective monocentric study focuses on the clinical outcomes of massive tibial allografts and their outcome's prediction. Between 1987 and 2022, the files of 148 massive tibial allografts were retrospectively reviewed (registration number B403201523492). Survival curves were calculated based on the allograft success or failure. Survival curves without revision surgery were calculated following the same design. Finally, multiple logistic regression models were set up to point out variables that influence the allograft survival. After 30 years, 87.2% of the patient retained limb function. However, 55% of the allograft failed and had to be removed (mean survival time is 20.06 ± 2.07 years (CI 16.0-24.1)). The estimate mean survival time is 10.26 ± 1.60 years (CI 7.1-13.4) with less than 20% survival for the allografts without revision surgery after 30 years. Tumor and septic indications worsen the prognosis as well as the number of revision surgeries and the osteochondral allograft type. In contrast, PSI use or traumatological indications improve the allograft survival. Despite remaining an excellent surgical reconstructive option, massive tibial allografts show a high revision surgery rate. Thanks to our multiple logistic regression models, we can start to predict and improve the final outcomes of these complex allograft reconstruction.</p>","PeriodicalId":9723,"journal":{"name":"Cell and Tissue Banking","volume":"26 2","pages":"23"},"PeriodicalIF":1.4000,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"How to predict structural allograft survival in tibial reconstructions.\",\"authors\":\"R Evrard, J Manon, P-L Docquier, O Cornu, T Schubert\",\"doi\":\"10.1007/s10561-025-10172-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Tibial reconstruction for major bone loss is a challenging surgical situation. For more than 30 years, massive bone allografts entered our therapeutic arsenal as a major tool to reconstruct large bone defect. Despite allograft is valued for its convenience, it is still burdened by a high complication rate. This retrospective monocentric study focuses on the clinical outcomes of massive tibial allografts and their outcome's prediction. Between 1987 and 2022, the files of 148 massive tibial allografts were retrospectively reviewed (registration number B403201523492). Survival curves were calculated based on the allograft success or failure. Survival curves without revision surgery were calculated following the same design. Finally, multiple logistic regression models were set up to point out variables that influence the allograft survival. After 30 years, 87.2% of the patient retained limb function. However, 55% of the allograft failed and had to be removed (mean survival time is 20.06 ± 2.07 years (CI 16.0-24.1)). The estimate mean survival time is 10.26 ± 1.60 years (CI 7.1-13.4) with less than 20% survival for the allografts without revision surgery after 30 years. Tumor and septic indications worsen the prognosis as well as the number of revision surgeries and the osteochondral allograft type. In contrast, PSI use or traumatological indications improve the allograft survival. Despite remaining an excellent surgical reconstructive option, massive tibial allografts show a high revision surgery rate. Thanks to our multiple logistic regression models, we can start to predict and improve the final outcomes of these complex allograft reconstruction.</p>\",\"PeriodicalId\":9723,\"journal\":{\"name\":\"Cell and Tissue Banking\",\"volume\":\"26 2\",\"pages\":\"23\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2025-05-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cell and Tissue Banking\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.1007/s10561-025-10172-5\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell and Tissue Banking","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1007/s10561-025-10172-5","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

胫骨重建是一项具有挑战性的手术情况。30多年来,大量同种异体骨移植进入我们的治疗武器库,作为重建大型骨缺损的主要工具。尽管同种异体移植因其方便而受到重视,但其并发症的发生率仍然很高。这项回顾性单中心研究的重点是大量胫骨同种异体移植的临床结果及其结果的预测。回顾性分析1987 - 2022年间148例大块胫骨同种异体移植物的资料(注册号B403201523492)。根据同种异体移植的成功或失败计算生存曲线。没有翻修手术的生存曲线按照相同的设计计算。最后,建立多元逻辑回归模型,指出影响同种异体移植物存活的变量。30年后,87.2%的患者保留肢体功能。然而,55%的同种异体移植物失败,不得不切除(平均生存时间为20.06±2.07年(CI 16.0-24.1))。估计平均生存时间为10.26±1.60年(CI 7.1-13.4), 30年后不进行翻修手术的同种异体移植物的存活率低于20%。肿瘤和脓毒症的适应症使预后、翻修手术次数和同种骨软骨移植类型恶化。相比之下,使用PSI或外伤指征可提高同种异体移植物的存活率。尽管大块胫骨同种异体移植物仍然是一种很好的手术重建选择,但其翻修手术率很高。由于我们的多元逻辑回归模型,我们可以开始预测和改善这些复杂的同种异体移植重建的最终结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
How to predict structural allograft survival in tibial reconstructions.

Tibial reconstruction for major bone loss is a challenging surgical situation. For more than 30 years, massive bone allografts entered our therapeutic arsenal as a major tool to reconstruct large bone defect. Despite allograft is valued for its convenience, it is still burdened by a high complication rate. This retrospective monocentric study focuses on the clinical outcomes of massive tibial allografts and their outcome's prediction. Between 1987 and 2022, the files of 148 massive tibial allografts were retrospectively reviewed (registration number B403201523492). Survival curves were calculated based on the allograft success or failure. Survival curves without revision surgery were calculated following the same design. Finally, multiple logistic regression models were set up to point out variables that influence the allograft survival. After 30 years, 87.2% of the patient retained limb function. However, 55% of the allograft failed and had to be removed (mean survival time is 20.06 ± 2.07 years (CI 16.0-24.1)). The estimate mean survival time is 10.26 ± 1.60 years (CI 7.1-13.4) with less than 20% survival for the allografts without revision surgery after 30 years. Tumor and septic indications worsen the prognosis as well as the number of revision surgeries and the osteochondral allograft type. In contrast, PSI use or traumatological indications improve the allograft survival. Despite remaining an excellent surgical reconstructive option, massive tibial allografts show a high revision surgery rate. Thanks to our multiple logistic regression models, we can start to predict and improve the final outcomes of these complex allograft reconstruction.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cell and Tissue Banking
Cell and Tissue Banking CELL BIOLOGY-ENGINEERING, BIOMEDICAL
CiteScore
3.10
自引率
13.30%
发文量
68
审稿时长
6-12 weeks
期刊介绍: Cell and Tissue Banking provides a forum for disseminating information to scientists and clinicians involved in the banking and transplantation of cells and tissues. Cell and Tissue Banking is an international, peer-reviewed journal that publishes original papers in the following areas: basic research concerning general aspects of tissue banking such as quality assurance and control of banked cells/tissues, effects of preservation and sterilisation methods on cells/tissues, biotechnology, etc.; clinical applications of banked cells/tissues; standards of practice in procurement, processing, storage and distribution of cells/tissues; ethical issues; medico-legal issues.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信